

10/ 533,931

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records

NEWS 31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 33	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:47:09 ON 24 JUL 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 17:48:02 ON 24 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES: 23 JUL 2008 HIGHEST RN 1035697-56-3
DICTIONARY FILE UPDATES: 23 JUL 2008 HIGHEST RN 1035697-56-3
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10533391b.str
```

10/ 533,931



```
chain nodes :
11 21 22 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20 23 24 25 26
27 28
chain bonds :
2-31 4-21 7-11 11-12 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 16-18 17-20 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :
2-31 4-21 7-11 11-12 21-22
exact bonds :
16-18 17-20 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 : 23 :
```

G1:i-Pr,[*1]

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
31:CLASS
```


L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

10/ 533,931



G1 i-Pr, [01]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:48:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:48:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 30 TO ITERATE

100.0% PROCESSED 30 ITERATIONS

26 ANSWERS

SEARCH TIME: 00.00.01

L3 26 SEA SSS FUL L1

=> file capllus

'CAPLLUS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.78

FILE 'CAPLUS' ENTERED AT 17:48:45 ON 24 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 23 Jul 2008 (20080723/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 4 L3

=> d 14 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:995977 CAPLUS

DOCUMENT NUMBER: 141:420417

TITLE: Therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis

INVENTOR(S): Curwen, Jon Owen; Wedge, Stephen Robert

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098604	A1	20041118	WO 2004-GB1939	20040504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004237132	A1	20041118	AU 2004-237132	20040504
AU 2004237132	B2	20071018		
CA 2519930	A1	20041118	CA 2004-2519930	20040504

EP 1620104	A1	20060201	EP 2004-731049	20040504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009742	A	20060509	BR 2004-9742	20040504
CN 1784232	A	20060607	CN 2004-80012089	20040504
JP 2006525304	T	20061109	JP 2006-506222	20040504
NO 2005004411	A	20051130	NO 2005-4411	20050923
US 20060223815	A1	20061005	US 2005-555389	20051103
MX 2005PA11858	A	20060217	MX 2005-PA11858	20051104
PRIORITY APPLN. INFO.:			GB 2003-10401	A 20030507
			WO 2004-GB1939	W 20040504
GI				



AB The invention relates to the use of an anti-angiogenic agent, such as I (preparation given), in combination with an inhibitor of the Src family of non-receptor tyrosine kinases, such as the II (preps. according to a previous patent given), in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis. The invention provides for the Src kinase inhibitor to be administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent. Thus, 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline was coupled with 1-acetylpiperazine using KI in DMA to give I. The diastolic blood pressure profile of rats over a 24 h period after administration of a combination of 1.5 mg/kg of I and 25 mg/kg of II demonstrated that the contrasting blood pressure effects of the antiangiogenic agent and the Src kinase inhibitor were substantially counterbalanced.

IT 692054-06-1, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy)pyridin-4-yl]amino]-5-isopropoxyquinazoline
692054-28-7, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-


methylenedioxy pyridin-4-yl) amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline
692054-33-4 692054-44-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Src kinase inhibitor; therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis)


RN 692054-06-1 CAPLUS

CN Ethanone, 1-[4-[2-[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl) amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS


CN Ethanone, 1-[4-[2-[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl) amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 692054-44-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857372 CAPLUS

DOCUMENT NUMBER: 141:350196

TITLE: Preparation of quinazoline derivatives as selective Src kinase inhibitors

INVENTOR(S): Curwen, Jon Owen

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087120	A2	20041014	WO 2004-GB1286	20040323
WO 2004087120	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2003-7333

A 20030329


AB The invention relates to the use of quinazoline derivative as a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke. For example, 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxyphenyl)-5-isopropoxyquinazoline administered to rats at 25 mg/kg p.o. on day 1 showed hypotensive effect of 25 mmHg on day 2.

IT 692054-44-7, 4-(5-Chloro-2,3-methylenedioxyphenyl)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]-5-isopropoxyquinazoline
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692054-44-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 692054-06-1P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxyphenyl)-5-isopropoxyquinazoline
 692054-28-7P, 4-(5-Chloro-2,3-methylenedioxyphenyl)-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-5-(tetrahydropyran-4-yloxy)quinazoline
 692054-33-4P, 4-(5-Chloro-2,3-methylenedioxyphenyl)-5-(tetrahydropyran-4-yloxy)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)


RN 692054-06-1 CAPLUS

CN Ethanone, 1-[4-[2-[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS


CN Ethanone, 1-[4-[2-[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 692054-33-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)


Relative stereochemistry.



- IT 692053-18-2P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxyphenyl)-5-(2,3-methylenedioxyphenyl)quinazolin-2-amine
 692053-23-9P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxyphenyl)-5-(2,3-methylenedioxyphenyl)quinazolin-2-amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (reactant; preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)
 RN 692053-18-2 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(2,3-methylenedioxyphenyl)oxy]- (CA INDEX NAME)



- RN 692053-23-9 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:430753 CAPLUS

DOCUMENT NUMBER: 141:1220

TITLE: Preparation of quinazolines as Src family non-receptor tyrosine kinase inhibitors for use in combination therapy with gemcitabine for treatment and prophylaxis of pancreatic cancer

INVENTOR(S): Barge, Alan

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043472	A1	20040527	WO 2003-GB4787	20031107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504666	A1	20040527	CA 2003-2504666	20031107
AU 2003279456	A1	20040603	AU 2003-279456	20031107
AU 2003279456	B2	20070517		
EP 1562612	A1	20050817	EP 2003-772404	20031107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016170	A	20050927	BR 2003-16170	20031107
CN 1711094	A	20051221	CN 2003-80103138	20031107
JP 2006508953	T	20060316	JP 2004-550784	20031107
NZ 539514	A	20071130	NZ 2003-539514	20031107
NO 2005002312	A	20050606	NO 2005-2312	20050511
ZA 2005003805	A	20060927	ZA 2005-3805	20050511
MX 2005PA05119	A	20050802	MX 2005-PA5119	20050512
US 20060142297	A1	20060629	US 2005-534721	20051020
PRIORITY APPLN. INFO.:			GB 2002-26434	A 20021113
			WO 2003-GB4787	W 20031107

GI



AB The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent, gemcitabine, a pharmaceutical composition comprising such a combination, and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer. Examples include preps. for anilino- and (pyridylamino)quinazoline Src inhibitors (no Markush structure given) and bioassays demonstrating the synergistic effect of treating pancreatic cancer with a quinazoline Src inhibitor in combination with gemcitabine. For instance, 4-amino-5-chloro-2,3-methylenedioxy pyridine was coupled with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation of reactants given) in the presence of sodium hexamethyldisilazane in THF to afford the (pyridylamino)quinazoline I. Nude mice were injected with pancreatic tumor cells derived from the COLO 357 human pancreatic cancer cell line and treated with gemcitabine, the Src inhibitor, 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or a combination of the two. Evaluation for tumor growth and incidence of liver metastases showed that, compared with the weight of control tumors, tumor growth in animals treated with the combination was much reduced (1359 mg and 124 mg, resp.) to a level well below that achievable on the dosing of either gemcitabine or the Src inhibitor alone. In addition, there was no liver metastasis in the animals treated with the combination, whereas liver metastasis was present in 1/5 of the animals treated with gemcitabine alone.


IT 692053-18-2P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline
 692053-23-9P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-isopropoxyquinazoline
 692053-39-7P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-7-(3-chloropropoxy)-5-[(tetrahydropyran-4-yl)oxy]quinazoline
 692053-44-4P, 4-[(5-Chloro-2,3-methylenedioxy pyridin-4-yl)amino]-7-[(2,4-dimethoxybenzyl)oxy]-5-isopropoxyquinazoline 692053-55-7P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]-5-isopropoxyquinazoline 692055-28-0P, 5-Isopropoxy-7-[2-(piperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxy pyridin-4-yl)amino]quinazoline
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antitumor agent; preparation of quinazoline-containing Src inhibitors for use in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692053-18-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)

10/ 533,931




RN 692053-23-9 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-39-7 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-44-4 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (CA INDEX NAME)

10/ 533,931




RN 692053-55-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692055-28-0 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



IT 692053-49-9P, 4-[(5-Chloro-2,3-methylenedioxy)pyridin-4-yl]amino]-7-hydroxy-5-isopropoxyquinazoline 692053-72-8P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxy)pyridin-4-yl]amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-76-2P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxy)pyridin-4-yl]amino]-5-isopropoxyquinazoline 692053-82-0P, 4-[(5-Chloro-2,3-methylenedioxy)pyridin-4-yl]amino]-7-[2-[4-(2-dimethylaminoacetyl)piperazin-1-yl]ethoxy]-5-isopropoxyquinazoline

692054-06-1P, 5-Isopropoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline
 692054-28-7P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692054-33-4P 692054-44-7P
 692055-04-2P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-10-0P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-16-6P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-22-4P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-34-8P, 5-Isopropoxy-7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-41-7P, 5-Isopropoxy-7-[2-(pyrrolidin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-46-2P, 5-Isopropoxy-7-[2-(piperidino)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-53-1P, 5-Isopropoxy-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-59-7P, 5-Isopropoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-76-8P, 5-Isopropoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline 692055-83-7P, 5-Isopropoxy-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxyppyridin-4-yl)amino]quinazoline
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antitumor agent; preparation of quinazoline-containing Src inhibitors for

use

in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)


RN 692053-49-9 CAPLUS

CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (CA INDEX NAME)




RN 692053-72-8 CAPLUS

CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 692053-76-2 CAPLUS

CN	Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)
----	--



RN 692053-82-0 CAPLUS


CN Ethanone, 1-[4-[2-[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl) amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 692054-06-1 CAPLUS


CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)

10/ 533,931



RN 692054-28-7 CAPLUS


CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 692054-44-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)


10/ 533,931

Relative stereochemistry.




RN 692055-04-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-10-0 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-16-6 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)

10/ 533,931




RN 692055-22-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-34-8 CAPLUS


CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 692055-41-7 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)

10/ 533,931




RN 692055-46-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 692055-53-1 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 692055-59-7 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)

10/ 533,931




RN 692055-76-8 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 692055-83-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



IT 692060-97-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinazoline-containing Src inhibitors for use in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692060-97-2 CAPLUS


CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

10/ 533,931

CM 1

CRN 692053-49-9


CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:414727 CAPLUS

DOCUMENT NUMBER: 140:423698

TITLE: Preparation of quinazoline derivatives as c-Src tyrosine kinase inhibitors

INVENTOR(S): Ple, Patrick

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004041829	A1	20040521	WO 2003-GB4703	20031029
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2503371	A1	20040521	CA 2003-2503371	20031029
AU 2003278383	A1	20040607	AU 2003-278383	20031029
AU 2003278383	B2	20070614		
EP 1562955	A1	20050817	EP 2003-769689	20031029
EP 1562955	B1	20080227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015756	A	20050906	BR 2003-15756	20031029
CN 1735617	A	20060215	CN 2003-80108194	20031029
JP 2006506463	T	20060223	JP 2005-502127	20031029
NZ 539408	A	20070928	NZ 2003-539408	20031029
AT 387451	T	20080315	AT 2003-769689	20031029
ES 2300619	T3	20080616	ES 2003-769689	20031029
IN 2005DN01534	A	20061229	IN 2005-DN1534	20050415
NO 2005001900	A	20050601	NO 2005-1900	20050419
ZA 2005003337	A	20060726	ZA 2005-3337	20050425
MX 2005PA04858	A	20050722	MX 2005-PA4858	20050504
US 20060122199	A1	20060608	US 2005-533931	20050504
PRIORITY APPLN. INFO.:			EP 2002-292736	A 20021104
			EP 2003-290900	A 20030410
			WO 2003-GB4703	W 20031029
OTHER SOURCE(S):	MARPAT 140:423698			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = halo, CF3, cyano, isocyano, NO3, OH, SH, amino,
 formyl, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; Z = O,
 SO, SO2, N(R2)2, or C(R2)2; R2 = H or alkyl; m = 0-3; R3 = halo, CF3, CN,
 NO2, OH, amino, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.;
 n = 0-3] were prepared as c-Src tyrosine kinase inhibitors in the containment
 and/or treatment of solid tumor disease. For example, reaction of
 4-amino-5-chloro-2,3-methylenedioxy pyridine (preparation given) and
 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation given) yielded
 compound II.

IT 692053-18-2P 692053-23-9P 692053-39-7P
 692053-44-4P 692053-49-9P 692053-55-7P
 692055-28-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)


RN 692053-18-2 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-
 chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)

10/ 533,931




RN 692053-23-9 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-39-7 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-44-4 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (CA INDEX NAME)

10/ 533,931




RN 692053-49-9 CAPLUS

CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (CA INDEX NAME)




RN 692053-55-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692055-28-0 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)




IT 692053-72-8P 692053-76-2P 692053-82-0P
 692054-06-1P 692054-28-7P 692054-33-4P
 692054-44-7P 692055-04-2P 692055-10-0P
 692055-16-6P 692055-22-4P 692055-34-8P
 692055-41-7P 692055-46-2P 692055-53-1P
 692055-59-7P 692055-76-8P 692055-83-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)


RN 692053-72-8 CAPLUS

CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-
 2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX
 NAME)



RN 692053-76-2 CAPLUS


CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-
 methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



10/ 533,931


RN 692053-82-0 CAPLUS

CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 692054-06-1 CAPLUS

CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS

CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 692054-33-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-

10/ 533,931

[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-
[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 692054-44-7 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692055-04-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



10/ 533,931


RN 692055-10-0 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)




RN 692055-16-6 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-22-4 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-34-8 CAPLUS


CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

10/ 533,931




RN 692055-41-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 692055-46-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 692055-53-1 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 692055-59-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 692055-76-8 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 692055-83-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

10/ 533,931



IT 692060-97-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)


RN 692060-97-2 CAPLUS

CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 692053-49-9


CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



=> d his

(FILE 'HOME' ENTERED AT 17:47:09 ON 24 JUL 2008)

10/ 533,931

FILE 'REGISTRY' ENTERED AT 17:48:02 ON 24 JUL 2008

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 26 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:48:45 ON 24 JUL 2008

L4 4 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.28

201.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

STN INTERNATIONAL LOGOFF AT 17:49:22 ON 24 JUL 2008